Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05052931 | Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 10 | Jianjun YangOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05721651 | Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study | unknown | Phase 2 | 60 | Wu JunOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03918499 | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 9 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05541146 | Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT02954536 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05536102 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | recruiting | Phase 2 | 38 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05750290 | CKD-702 Plus Irinotecan in Gastric Cancer | unknown | Phase 2 | 40 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05720533 | Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 9, 2023 | clinicaltrials |
| NCT04099641 | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | completed | Phase 2 | 80 | OncXerna Theraputics, Inc.INDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03995017 | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma(RiME) | unknown | Phase 1 / Phase 2 | 34 | University of Kansas Medical CenterOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02501603 | Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer | completed | Phase 2 | 72 | Yonsei UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | completed | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04168931 | Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC(GASTHER2) | terminated | Phase 2 | 5 | AC Camargo Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT05648487 | HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis | not yet recruiting | Phase 2 | 46 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05643677 | Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 47 | Fujian Medical UniversityOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT02191566 | S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy(SOHUG) | terminated | Phase 2 | 8 | Kangbuk Samsung HospitalOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05300945 | HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 200 | Zhixin CaoOTHER | 0 | Dec 6, 2022 | clinicaltrials |
| NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | unknown | Phase 2 | 19 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05627414 | Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 25, 2022 | clinicaltrials |
| NCT05618821 | Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer | recruiting | Phase 2 | 68 | Fujian Medical UniversityOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT04744649 | Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial(NICE) | unknown | Phase 2 | 110 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT00911820 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT05594381 | A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma. | unknown | Phase 2 | 90 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT01665274 | Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer(repeat) | terminated | Phase 2 | 15 | Harbin Medical UniversityOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05545436 | Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer | unknown | Phase 2 | 34 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT03755440 | PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. | completed | Phase 2 | 6 | Sun Yat-sen UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05528367 | Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | not yet recruiting | Phase 2 | 203 | Fujian Medical UniversityOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05519202 | Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer | unknown | Phase 2 | 47 | The Central Hospital of Lishui CityOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT05024812 | Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | unknown | Phase 1 / Phase 2 | 64 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT02725424 | Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer(MATCH) | completed | Phase 2 | 180 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05497739 | Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2022 | clinicaltrials |
| NCT02661971 | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)(RAMSES/FLOT7) | completed | Phase 2 / Phase 3 | 180 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT01854255 | Intraperitoneal Aerosol Chemotherapy in Gastric Cancer(PIPAC-GA01) | completed | Phase 2 | 35 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05439993 | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma | unknown | Phase 1 / Phase 2 | 42 | Hallym University Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Apr 13, 2023source: clinicaltrials